ストックスクリーナーアプリを入手
4.10
1.10%
-0.05
前日終値:
$4.15
開ける：
$4.13
24時間の取引高:
1.70M
Relative Volume:
0.34
時価総額：
$1.32B
収益：
$360.78M
当期純損益:
$-23.91M
株価収益率:
-52.50
EPS:
-0.0781
ネットキャッシュフロー:
$13.07M
1週間 パフォーマンス:
+5.24%
1か月 パフォーマンス:
-0.62%
6か月 パフォーマンス:
-25.91%
1年 パフォーマンス:
-0.13%
1日の値動き範囲:
$4.06
$4.14
1週間の範囲:
$3.87
$4.40
52週間の値動き範囲:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Compare MNKD vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.105 | 1.37B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
550.42 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
829.89 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,014.42 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.13 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-10-10 | 開始されました | Leerink Partners | Outperform |
| 2025-07-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MNKD Stock Price, Quote & Chart - ChartMill
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD - marketbeat.com
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale - Stock Titan
Danbury biopharma company expands workforce, manufacturing amid new product launches - Hartford Business Journal
MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating - MarketBeat
Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD - MarketBeat
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 By Investing.com - Investing.com South Africa
MNKD Maintained by Wells Fargo -- Price Target Lowered to $13.00 - GuruFocus
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says - Yahoo Finance
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 - Investing.com
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth - GuruFocus
MannKind Q2 Earnings Call Highlights - marketbeat.com
MNKD SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 By Investing.com - Investing.com Nigeria
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 - Investing.com
Is MannKind Corp (MNKD) Positioned for Growth After Q2 Earnings? - GuruFocus
MannKind Q2 2026 slides: revenue surges 43%, marketed products lead - Investing.com
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MannKind: Q2 Earnings Snapshot - Barchart.com
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary - TradingView
MannKind (NASDAQ: MNKD) posts $199M H1 2026 revenue after scPharma deal - Stock Titan
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
MannKind earnings in focus after FUROSCIX ReadyFlow approval By Investing.com - Investing.com Nigeria
MannKind Corp expected to post breakeven results a shareEarnings Preview - TradingView
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Reports Positive Topline Results from Phase 1b INFLO-1 Study of Nintedanib Dry Powder Inhalation in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF - GlobeNewswire
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway - Yahoo Finance
MannKind will review second-quarter results in Aug. 5 webcast - Stock Titan
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
0.28%
大文字化:
|
ボリューム (24 時間):